🟢 NanoViricides is trading 5% up in pre-market with no clear company-specific catalyst identified

NanoViricides is trading at $1.56, up 5.39% in the October 21 pre-market, with no clear overnight company-specific catalyst identified. - On October 20, NanoViricides announced juvenile-mouse safety and tolerability findings for NV-387; available reporting does not establish the announcement as the cause of the move. - Biotech-sector strength may be supporting shares; provided context reports XBI up 3.64% pre-market. - Shares rose 13.85% in the October 20 session, so the current gain follows a sharp prior-session advance.